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ARTICLE
Critical role for arginase 2 in obesity-associated
pancreatic cancer
Tamara Zaytouni1,2,3, Pei-Yun Tsai1,2, Daniel S. Hitchcock3, Cory D. DuBois1,3, Elizaveta Freinkman4,8, Lin Lin2,
Vicente Morales-Oyarvide5, Patrick J. Lenehan1,2, Brian M. Wolpin5, Mari Mino-Kenudson 6,
Eduardo M. Torres7, Nicholas Stylopoulos1,2,3, Clary B. Clish 3 & Nada Y. Kalaany 1,2,3
Obesity is an established risk factor for pancreatic ductal adenocarcinoma (PDA). Despite
recent identiﬁcation of metabolic alterations in this lethal malignancy, the metabolic
dependencies of obesity-associated PDA remain unknown. Here we show that obesity-driven
PDA exhibits accelerated growth and a striking transcriptional enrichment for pathways
regulating nitrogen metabolism. We ﬁnd that the mitochondrial form of arginase (ARG2),
which hydrolyzes arginine into ornithine and urea, is induced upon obesity, and silencing or
loss of ARG2 markedly suppresses PDA. In vivo infusion of 15N-glutamine in obese mouse
models of PDA demonstrates enhanced nitrogen ﬂux into the urea cycle and infusion of 15N-
arginine shows that Arg2 loss causes signiﬁcant ammonia accumulation that results from the
shunting of arginine catabolism into alternative nitrogen repositories. Furthermore, analysis of
PDA patient tumors indicates that ARG2 levels correlate with body mass index (BMI). The
speciﬁc dependency of PDA on ARG2 rather than the principal hepatic enzyme ARG1 opens a
therapeutic window for obesity-associated pancreatic cancer.
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Pancreatic ductal adenocarcinoma (PDA) is a deadlymalignancy with an incidence on the rise1, 2. Parallel tothis rise has been a surge in obesity and the metabolic
syndrome, established risk factors for PDA3–7. Recent studies
of tumor metabolism identiﬁed KRAS-driven alterations in
nutrient scavenging and utilization that are critical for the
maintenance of PDA tumors8–10, the vast majority of which
(>90%) harbor activating KRAS mutations. However, whether
these or other metabolic alterations occur in obesity-associated
PDA remains unknown. Here we perform unbiased tran-
scriptomic and metabolomic analyses on orthotopic transplant
models of PDA, and identify striking alterations in nitrogen
metabolism in PDA tumors of the obese. In particular, we ﬁnd
that arginase 2 (ARG2), the extrahepatic mitochondrial enzyme
that catabolizes arginine into ornithine and urea is induced upon
obesity. This induction is accompanied by enhanced PDA growth
and increased nitrogen ﬂux from 15N-glutamine into the
urea cycle, the principal mammalian pathway for ammonia
detoxiﬁcation, usually operating in the liver. We ﬁnd that
silencing or loss of ARG2 in human or mouse tumors respec-
tively, strongly suppresses PDA growth, particularly in obese
hosts. Infusion of 15N-arginine in murine orthotopic transplant
models of PDA demonstrates that Arg2 deﬁciency causes
shunting of arginine catabolism away from the urea cycle and
into creatine synthesis, resulting in signiﬁcant accumulation of
ammonia speciﬁcally in tumors of the obese. Our ﬁndings point
to an essential in vivo role for ARG2 in pancreatic cancer, an
insidious malignancy with enhanced protein breakdown and
remodeling11–16, and suggest a potential need for the channeling
of nitrogen into the urea cycle in highly proliferative tumors.
Importantly, because ARG1 and not ARG2 is the main hepatic
ureagenic enzyme in mammals17–21, speciﬁc targeting of ARG2
may provide a therapeutic opportunity for the treatment of
pancreatic cancer patients, particularly those suffering from
obesity and the metabolic syndrome.
Results
Nitrogen metabolism genes are induced in PDA of the obese.
To identify metabolic dependencies in obesity-driven pancreatic
cancer, KRAS-mutant human AsPC-1 cells expressing cerulean
ﬂuorescent protein (AsPC1-CFP) were used to generate lean and
obese orthotopic xenograft models of PDA, as outlined in Fig. 1a.
High fat diet-fed “obese” mice gained signiﬁcantly more weight
(P≤ 0.0001, two-way ANOVA followed by Tukey test) than their
chow-fed “lean” counterparts (Fig. 1b and Supplementary Fig. 1a)
and displayed features of the metabolic syndrome (Supplemen-
tary Fig. 1b–e). The lean and obese mice were then injected
orthotopically into their pancreata with AsPC1-CFP cells
and maintained on their corresponding diets for 6 weeks prior
to tumor harvest (Fig. 1a). The resulting tumors were termed
“Lean-CFP” and “Obese-CFP”, according to the metabolic state of
the mouse. Consistent with a role for obesity in promoting
PDA growth, Obese-CFP tumors grew signiﬁcantly larger
(1.5-fold, P= 0.002, t-test) than Lean-CFP (Fig. 1c). A mild
stromal inﬁltration was observed in all PDA tumors, independent
of obesity (Supplementary Fig. 2).
To identify obesity-associated transcriptional alterations in
PDA, comparative microarray expression analysis was performed.
Gene set enrichment analysis (GSEA)22 revealed a striking over-
representation of KEGG-deﬁned pathways involved in “Nitrogen
Metabolism” (FDR q-value= 0.003; P< 0.001), “Alanine,
Aspartate and Glutamate Metabolism” (FDR q-value= 0.172;
P= 0.028), and “Arginine and Proline Metabolism” (FDR
q-value= 0.245; P= 0.011) in Obese-CFP compared to Lean-
CFP tumors (Fig. 1d). Notably, there was increased expression of
glutaminase (GLS) and glutamate dehydrogenase (GLUD), which
catalyze the deamination of glutamine and glutamate, respec-
tively, generating ammonia. Expression of aspartate transaminase
(GOT), which transfers the amino group from glutamate to
oxaloacetate (OAA), generating aspartate was also upregulated
(Fig. 1d). Moreover, there was induction in the rate-limiting
enzyme in arginine biosynthesis, argininosuccinate synthetase
(ASS1). In addition, mRNA levels of the mitochondrial,
extrahepatic form of arginase (ARG2) were elevated. This is in
contrast to its paralog (ARG1), which codes for the hepatic
cytosolic form of arginase, the principal ureagenic enzyme that
catalyzes the ﬁnal step in nitrogen excretion and ammonia
detoxiﬁcation (Fig. 1d). Whereas ARG1 protein levels were faintly
detected, those of ARG2 were induced in Obese-CFP compared
to Lean-CFP tumors (Fig. 1e). These results imply a potential
role for the urea cycle in PDA growth, as nitrogens from
both ammonia and aspartate get incorporated into arginine and
ultimately urea. Importantly, urea levels in the tumors
were comparable to those in the liver, where the urea cycle
largely operates, indicating that this pathway is indeed active in
PDA (Fig. 1f).
ARG2 is critical for PDA growth particularly in the obese. To
investigate its role in PDA tumor growth, ARG2 was knocked-
down in AsPC-1 cells (Fig. 2a). Compared with control scramble
knockdown (AsPC1-shScr), ARG2 silencing (AsPC1-shARG2)
did not signiﬁcantly affect PDA cell proliferation in vitro
(Fig. 2b), nor did it lead to compensatory increases in ARG1
levels (Fig. 2a). This was consistent among other human PDA
cells (Supplementary Fig. 3). To assess ARG2 activity, AsPC1-
shScr and AsPC1-shARG2 cells were labeled with 13C6-arginine,
followed by a measure of 13C-labeled ARG2 reaction products by
liquid chromatography-mass spectrometry (LC–MS). Enrichment
in 13C-labeled urea M1 (3.8%) and ornithine M5 (17.8%) was
noted in the AsPC1-shScr control cells. These levels were strongly
suppressed (urea 1.4%; ornithine 6.8%) upon ARG2 silencing
(P≤ 0.001, one-way ANOVA followed by Tukey test, Fig. 2c),
indicating that ARG2 was indeed active in PDA cells. Surprisingly
however, when the cells were labeled with 15N(amine)-glutamine,
15N-labeling was detected in glutamate, aspartate and
carbamoyl aspartate (60–70%), the precursor of pyrimidine
synthesis (Fig. 2d, e), but not in urea cycle metabolites citrulline,
arginine or urea. These results indicate that although ARG2 is
expressed and active in PDA cells in vitro, the amine nitrogen of
glutamine is not disposed of through the urea cycle.
Because ARG2 was induced in obesity-associated tumors
(Fig. 1d, e), we asked whether its role in PDA growth was
relevant in an in vivo, rather than in vitro setting. When PDA
cells were grown as orthotopic xenografts in lean or obese mice
(Fig. 1a and Supplementary Fig. 4a, b), a moderate decrease in
tumor volume was noted in lean mice upon ARG2 knockdown
(1.7-fold, Fig. 3a). However, this effect was more dramatic in
obese mice, where only half of the AsPC1-shARG2 tumors grew
to a measurable size, reaching volumes 2.1-fold smaller than those
of the control shScr tumors (P≤ 0.0001, one-way ANOVA
followed by Tukey test), with the exception of one AsPC1-
shARG2 tumor that was similar in size to the control knockdown
(~150 mm3, black data point, Fig. 3a). Consistent with a strong
dependence of obesity-associated PDA on ARG2, this tumor had
re-expressed ARG2 in vivo (Fig. 3b, lane 11). Introduction of a
short hairpin RNA-resistant form of human ARG2 (Fig. 3c)
rescued the growth of these tumors compared to tumors
overexressing control GFP, where ARG2 knockdown caused a
2.2-fold suppression (P≤ 0.05, one-way ANOVA followed by
Tukey test, Fig. 3d, e).
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Fig. 1 Obesity leads to enhanced PDA growth and transcriptional induction of nitrogen and arginine metabolism. a Schematic timeline for the generation of
lean or obese orthotopic xenograft models of PDA, using 4–6 week old male Rag1−/− mice. b Growth curves of Lean-CFP (n= 15) or Obese-CFP (n= 14)
mice. Arrow indicates orthotopic injection of AsPC1-CFP cells (105 per mouse). c Volumes of orthotopic PDA tumors from mice in b. d Heatmaps (left) of
genes enriched in metabolic pathways in Lean-CFP compared to Obese-CFP tumors (n= 9 per group), with corresponding GSEA plots (right). Red indicates
higher expression, and blue lower expression, relative to the mean expression level within each group. NES normalized enrichment scores, FDR false discovery
rate, Nom. nominal. e Immunoblots for ARG2 and ARG1 in representative orthotopic tumors from c. f Graph demonstrating that the urea levels in PDA
tumors are comparable to those in the liver of lean or obese mice (n= 5); data are representative of three independent experiments. In b, data represent
the mean± s.e.m. In c, f, data represent the mean± s.d. *P≤ 0.05, **P≤ 0.01, ****P≤ 0.0001, two-way ANOVA followed by Tukey test in b and t-test in c
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To investigate the role of ARG2 in the metabolism of
pancreatic tumors, we performed unbiased global metabolite
proﬁling and found that nitrogen-centric pathways enriched in
urea cycle metabolites were highly impacted by ARG2 knockdown
(Supplementary Fig. 4c). Indeed, ARG2 suppression led to a block
in the urea cycle in tumors from both lean and obese animals,
causing signiﬁcant accumulation of glutamine, aspartate, argi-
nine, a less signiﬁcant but evident increase in the levels of
glutamate, citrulline and argininosuccinate, and a concomitant
decrease in ornithine levels (P≤ 0.05, one-way ANOVA followed
by Tukey test, Fig. 3f). Moreover, although urea is a highly
soluble, secreted metabolite, a modest decrease in its levels was
nonetheless observed in tumors of the obese but not the lean
(Fig. 3g). Altogether, these data suggest an increased dependence
of obesity-associated tumors on ARG2 for nitrogen disposal.
Obesity enhances nitrogen ﬂux into the urea cycle in PDA. To
trace the fate of nitrogen from glutamine into the urea cycle, lean,
and obese mice bearing orthotopic PDA tumors were infused
over a period of 3 h with 15N(amine)-glutamine, reaching steady-
state plasma enrichment levels of ~60% within the ﬁrst 30 min
(Fig. 4a, b). This enrichment led to the 15N-labeling of glutamine,
glutamate, and aspartate in PDA tumors (Fig. 4c). However, in
contrast to the results obtained from cultured PDA cells (Fig. 2d,
e), 15N-labeling was also detected in citrulline M1, arginine M1
and M2, and urea M1 and M2, reaching signiﬁcantly higher levels
in tumors of the obese compared with the lean (P≤ 0.01, one-way
ANOVA followed by Tukey test, Fig. 4d). These results provide
evidence for an in vivo nitrogen ﬂow from glutamine into urea in
PDA tumors, and indicate that this ﬂow is further enhanced in an
obese state.
Interestingly, although arginine donates its glutamine-derived
nitrogens to urea, but not ornithine, upon arginase activity
(Fig. 4b), signiﬁcant 15N-labeling in ornithine M1 and M2 was
detected in the PDA tumors (Fig. 4d). This labeling is a result of
de novo ornithine biosynthesis, catalyzed by ornithine amino-
transferase (OAT), where glutamate-dependent transamination of
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glutamate-γ-semialdehyde, produces ornithine M1 or M2
(Fig. 4b). As a consequence, M2- and M3-labeled citrulline, and
to a lesser extent M3-labeled arginine, were also detected, and the
abundance of M2- and M3-citrulline was signiﬁcantly increased
in PDA of the obese, compared to the lean (P≤ 0.01, one-way
ANOVA followed by Tukey test, Fig. 4b, d). Furthermore, ARG2
knockdown strongly and speciﬁcally suppressed 15N-ornithine
production in PDA tumors of obese, compared with lean mice
(M1, P≤ 0.05 and M2, P≤ 0.01, one-way ANOVA followed by
Tukey test, Fig. 4d). The enhanced incorporation of 15N from
glutamine into the urea cycle through ornithine biosynthesis and
its suppression upon ARG2 silencing provides further evidence
for the need to dispose of excess nitrogen in tumors of the obese.
Interestingly however, only a mild decrease in urea M1 and M2
levels was observed upon ARG2 knockdown, likely due to the
short duration of the infusions and the secretion of this highly
soluble metabolite (Fig. 4d). Because the urea cycle mainly
functions to prevent accumulation of toxic ammonia by
converting excess nitrogen into ornithine and urea, we quantiﬁed
15N-ammonia levels derived from 15N-glutamine, following its
chemical derivatization with dansyl chloride23. Consistent with
an increase in nitrogen levels in obesity-associated PDA, we
found a signiﬁcant accumulation of 15N-ammonia in tumors of
the obese, the levels of which tended to further increase upon
ARG2 knockdown (P≤ 0.05, one-way ANOVA followed by
Tukey test, Fig. 4e).
Arg2 loss causes ammonia accumulation in PDA of the obese.
To reinforce our ﬁndings and conﬁrm a role for the urea cycle in
PDA tumor growth, we sought to generate a PDA model with
complete loss, rather than knockdown, of arginase 2. To that end,
we bred the genetically engineered mouse model of PDA,
LSL-KrasG12D;p53ﬂ/ﬂ; pdx-1-Cre; (KPC mice) to Arg2-deﬁcient
mice, which express an aberrant, inactive form of the protein21
(Supplementary Fig. 5a). Resultant tumors were used to generate
KPC tumor cell lines with wild-type Arg2 expression (Arg2+/+) or
Arg2 loss (Arg2−/−) as conﬁrmed by genotyping21 (Fig. 5a). Arg2
loss caused a moderate but signiﬁcant decrease in the prolifera-
tion of KPC cells in vitro (P≤ 0.0001, one-way ANOVA followed
by Tukey test, Fig. 5b). These cells were then grown as orthotopic
PDA allografts in Kras- and Arg2-wild-type littermates.
Consistent with the results from human PDA (Fig. 1c), mouse
PDA tumor growth was accelerated by obesity (Fig. 5c). Impor-
tantly, when tumors were harvested at an early stage of pro-
gression (average size~ 165 mm3), loss of Arg2 led to a more
signiﬁcant suppression of tumor growth in obese compared to
lean mice (3.2-fold, P≤ 0.05, one-way ANOVA, followed by
Tukey test, Fig. 5c). This differential effect was strikingly more
evident in more advanced tumors (~800 mm3), where a dramatic
decrease in growth was observed in the obese (5.3-fold, P≤ 0.01,
one-way ANOVA, followed by Tukey test), but not in the lean
(Supplementary Fig. 5b).
We then investigated the metabolic effect of Arg2 deﬁciency on
nitrogen metabolism in KPC tumors. We reasoned that infusing
heavy labeled arginine, the substrate of Arg2, would convey direct
information concerning rapid accumulation of ammonia and
alternative fates of excess nitrogen due to Arg2 loss. To that end,
15N4,13C6-labeled arginine was infused for 3 h in lean and obese
mice bearing tumors with or without Arg2 loss (KPC; Arg2−/− or
KPC; Arg2+/+), and metabolic tracing of 15N and 13C into the
urea cycle was performed (Fig. 5d–h). As expected, Arg2
deﬁciency led to mild non-signiﬁcant increases in total levels of
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arginine and lower levels of ornithine (Fig. 5f). No signiﬁcant
changes in the relative abundance of intratumoral 15N-urea
M2 were observed in Arg2−/− tumors (Fig. 5g), likely due to the
short infusion period, and the secretion of urea from surrounding
Arg2+/+ cells. Nevertheless, a mild decrease in total levels of urea
was noted in the Arg2−/− tumors of the obese (Fig. 5f).
Consistently, Arg2 loss resulted in signiﬁcantly increased
levels of 15N-arginine M4 and M2 in obesity-associated tumors
(P≤ 0.05, one-way ANOVA, followed by Tukey test). This was
accompanied by a notable shift in arginine catabolism towards
creatine biosynthesis (Fig. 5e, g). The ﬁrst step in this pathway is
catalyzed by Gatm (glycine amidinotransferase, mitochondrial)
and involves the transfer of a guanidino group from arginine to
glycine, yielding ornithine and guanidinoacetate, the immediate
precursor of creatine (Fig. 5e). Indeed, the relative abundance of
15N,13C-creatine (M2, M1) and creatinine (M2, M1) was
signiﬁcantly increased in tumors with Arg2 deﬁciency, particu-
larly in the obese (P≤ 0.05 and P≤ 0.01, respectively, one-way
ANOVA followed by Tukey test, Fig. 5g).
Notably, Arg2 deﬁciency caused a signiﬁcant increase in labeled
aspartate M1 and glutamine M2, speciﬁcally in tumors of the
obese (P≤ 0.05, Fig. 5g), accompanied by a striking accumulation
in 15N-ammonia labeled fraction derived from 15N4,13C6-arginine
(4% in obese compared to 2.8% in lean, P≤ 0.001, one-way
ANOVA followed by Tukey test, Fig. 5h). The speciﬁc
accumulation of labeled glutamine, aspartate and ammonia from
15N4,13C6-arginine in Arg2-deﬁcient tumors of the obese results
from the shunting of arginine into ornithine by Gatm followed by
a transamination reaction catalyzed by Oat to form glutamate-γ-
semialdehyde M1 and α-KG-derived glutamate M1 (Fig. 5e).
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Labeled glutamate can also result from the conversion of Δ1-
pyrroline-5-carboxylate (P5C, a tautomer of glutamate-γ-
semialdehyde, Fig. 4b), by aldehyde dehydrogenase family 4
member A1 (Aldh4a1, Fig. 5e). Excess nitrogen can be transferred
from glutamate to aspartate (by Got) or to ammonia (via Glud),
while excess ammonia is subsequently utilized by glutamine
synthetase (Gs) to generate glutamine (Fig. 5e, g, h). The shunting
of arginine from the urea cycle towards alternative nitrogen-
containing metabolites (creatine, creatinine, aspartate, and
glutamine) upon Arg2 loss, along with the dramatic accumulation
of ammonia speciﬁcally in tumors of the obese, emphasize a role
for the urea cycle in nitrogen disposal in obesity-associated PDA.
Enhanced in vivo tumor growth induces ARG2 expression. The
crucial role of ARG2 in PDA tumor growth in vivo, but not
in vitro, led us to investigate whether candidate metabolites or
growth factors that are elevated in obesity24 (Supplementary
Fig. 1c–e), could lead to the induction of ARG2 expression.
Interestingly, treatment of cultured human PDA cells (AsPC-1,
HPAC and SUIT-2) with insulin (5–50 ng ml−1), insulin-like
growth factor-1 (IGF-1, 5–100 ng ml−1), glucose (3–11 mM), or a
chemically deﬁned lipid mixture (0.1–2%) did not affect ARG2
levels (Supplementary Fig. 6a, b). These results, along with a
recognized association of PDA tumors with enhanced protein
catabolism8, 11–15, 25, led us to hypothesize that obesity-induced
PDA tumor growth could generate an in vivo dependency on the
urea cycle for disposal of excess nitrogen.
We therefore sought to investigate the role of ARG2 in an
obesity-independent model of PDA with enhanced tumor growth.
To that end, we generated AsPC-1 PDA cells with constitutive
activation of AKT, a kinase known to promote tumor growth and
invasion26, 27. Unlike AsPC-1 parental and AsPC1-CFP cells,
AsPC1-AKT exhibited AKT activation and a proliferative
capacity that are independent of serum, insulin or IGF-1 (Fig. 6a
and Supplementary Fig. 7a–c). These cells were used to generate
“Lean-AKT” and “Obese-AKT” orthotopic tumors, in parallel to
the Lean-CFP and Obese-CFP tumors generated from the
isogenic AsPC1-CFP cells (Fig. 1a–c, Fig. 6b and Supplementary
Fig. 8a–e). Notably, independent of obesity, the volumes of
AsPC1-AKT tumors (Lean-AKT and Obese-AKT) were compar-
able to those of Obese-CFP tumors and 1.6-fold larger than
those of Lean-CFP (~170 versus 105mm3, P≤ 0.01 by one-way
ANOVA followed by Tukey test, compare Figs. 6b and 1c).
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Although this suggests a potential role for AKT in mediating the
obesity-driven increase in PDA growth3, 28–32, no signiﬁcant
changes in AKT phosphorylation (T308 or S473) were detected in
Obese-CFP compared to Lean-CFP tumors (n= 12, Fig. 6c and
Supplementary Fig. 9). These results indicate that obesity and
AKT activation are likely to be independent contributors to
enhanced in vivo PDA growth.
Strikingly, the transcriptional signature of AsPC1-AKT tumors
originating from either lean or obese mice signiﬁcantly over-
lapped with that of Obese-CFP, when compared to Lean-CFP
tumors (Supplementary Fig. 8f), suggesting that enhanced in vivo
tumor growth is a strong inducer of nitrogen metabolism and the
urea cycle. It is also possible that these metabolic changes
occurred as a result of acinar tissue disruption during AKT- or
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obesity-driven pancreatic tumor development. Consistently,
ARG2 expression was markedly increased in the tumors
harboring constitutively active AKT, independent of obesity
(P≤ 0.001, one-way ANOVA followed by Tukey test, Fig. 6d, e
and Supplementary Fig. 10a–c). Importantly, this increase was
only observed in tumors, but not in AsPC1-AKT cells propagated
in culture (Fig. 6f and Supplementary Fig. 10d), further
highlighting the in vivo, rather than in vitro relevance of ARG2
in PDA tumor growth. It however remains to be investigated
whether AKT activation results in an enhanced in vivo nitrogen
ﬂux into the urea cycle similar to that observed in obesity-driven
PDA. Although the transcriptional mechanism leading to in vivo
ARG2 induction is yet to be identiﬁed, these results are consistent
with a possible reliance on the urea cycle for the disposal of excess
nitrogen in highly proliferative hypovascular tumors.
Such environment contrasts the in vitro setting, where cells
are standardly cultured in copious amounts of media, which
allows for the secretion and dilution of nitrogen-containing
metabolites. Indeed, ARG2 suppression did not affect the growth
of AsPC1-AKT cells, in vitro (Fig. 6f, g). However, when grown
as orthotopic xenografts in lean immunodeﬁcient mice,
PDA tumors with AKT activation were larger than control
CFP-expressing tumors (1.8-fold, P≤ 0.05), and displayed an
enhanced dependency on ARG2 (Fig. 6h, i). Whereas ARG2
knockdown led to a non-statistically signiﬁcant two-fold decrease
in the volumes of CFP-expressing tumors, a signiﬁcantly stronger
suppression was noted in tumors with AKT activation (3.3-fold,
P≤ 0.01, one-way ANOVA followed by Tukey test, Fig. 6h).
ARG2 levels in PDA correlate with patient BMI. To extend the
relevance of our ﬁndings, we immunostained PDA tissue
microarrays from 92 patients with resected tumors, for ARG1,
ARG2, and phospho-S473 AKT (pAKT). Because ARG2
levels increase in diabetic patients and are mitigated by insulin
treatment33–35, patients with history of diabetes were excluded
from the study. Although PDA patients can lose weight as a result
of cachexia, over a third of the patient pool (38%) was reported as
overweight or obese at time of resection. Whereas signiﬁcant
ARG2 and pAKT staining was observed in the PDA tumors
(Fig. 6j, k), ARG1 was either undetected or weakly expressed.
Using multivariable-adjusted logistic regression models, we found
a signiﬁcant positive association between BMI and ARG2 levels
(P= 0.039, Fig. 6j, l). Notably, adjusting for pAKT levels only
mildly attenuated the signiﬁcance but not the strength of
this association (P= 0.051, Fig. 6l). In contrast, no signiﬁcant
association was found between BMI and pAKT. However, high
pAKT levels were strongly associated with high ARG2 expression,
independent of BMI (P= 0.010, Fig. 6k, l). These results corro-
borate our ﬁndings in the orthotopic PDA tumor models, where
AKT and obesity independently induce ARG2 expression.
Discussion
Our study highlights a role for the urea cycle in maintaining
the growth of pancreatic tumors, particularly in overweight
or obese systemic metabolic states. The dependency of PDA
tumors on ARG2, which catalyzes the ﬁnal step of the urea cycle,
suggests a need to alleviate an increased nitrogen burden,
particularly in an obese host, where tumors exhibit enhanced
in vivo growth. Pancreatic cancer is recognized for high-basal
levels of autophagy12, 15 and macropinocytic uptake of extra-
cellular proteins11, 13, 16, both of which can lead to enhanced
protein breakdown and remodeling14 to maintain tumor growth.
We therefore propose that conditions that enhance PDA growth
in vivo, such as obesity or AKT activation, might further
exaggerate this process, generating excess levels of nitrogen and
creating a dependency on ARG2. This dependency is speciﬁc to
tumors but not cultured cancer cells, which lack the in vivo tumor
microenvironment and are grown in a constantly replenished
medium, preventing the intracellular accumulation of nitrogen-
rich metabolites. Although our ﬁndings in orthotopic transplant
models remain to be conﬁrmed in an autochthonous mouse
model of PDA with Arg2 loss, they are in line with recent reports
highlighting the differential effects of in vitro versus in vivo
environments on the growth and metabolism of tumors from
different tissues25, 36–38. It is noteworthy that human disorders
have not been associated with ARG2 deﬁciency17. However, it
remains to be investigated whether defects in its activity cause
embryonic lethality. Nevertheless, whole body genetic deletion of
Arg2 in mice does not lead to signiﬁcant abnormalities, except for
a mild increase in circulating levels of arginine21. This is in
contrast with reported deﬁciencies in the predominantly hepatic
ARG1, which lead to robust hyperarginemia, neurological
impairment, growth retardation and fatal episodes of hyper-
ammonemia17–20. Consequently, ARG2 provides an attractive
therapeutic target in PDA patients, particularly those suffering
from obesity or those with AKT-driven PDA tumors resulting
from activating oncogenic mutations, independent of obesity.
Methods
Reagents. Antibodies for western blotting: AKT (#4691; 1:2000), pS473-AKT
(#4056; 1:1000), pT308-AKT (#4058; 1:500), PTEN (#9552; 1:1000) were
obtained from Cell Signaling Technologies, ARG1 (#ab133543; 1:500), human
ARG2 (#ab137069; 1:1000), mouse ARG2 (#bs-11397R; 1:2000) from Bioss
Antibodies and GAPDH (#sc-25778; 1:5000) from Santa Cruz. Antibodies for
immunoﬂuorescence were from Cell Signaling Technologies (pS473-AKT #4060;
1:50), abcam (α-SMA #ab5694; 1:200), Vector Laboratories (Biotinylated DBA-
Lectin #B-1035; 1:250), and Sigma-Aldrich (α-Amlyase #A8273; 1:1000).
Human recombinant Insulin (Roche, 11376497001), human recombinant IGF-1
(PeproTech, 100-11), D-Glucose (Sigma-Aldrich, G7021) and a chemically deﬁned
lipid mixture (sigma L0288) were used to treat cultured cells.
Cell culture. Human PDA cell lines were from the American Type Culture
Collection or ATCC (AsPC-1, HPAC, MIA PaCa-2, PANC-1), Japanese Collection
of Research Bioresources (SUIT-2), or the German Collection of Microorganisms
and Cell Cultures (PA-TU-8988T) and were authenticated by STR proﬁling at
ATCC. All cell lines tested negative for mycoplasma using LookOut Mycoplasma
PCR Kit (Sigma, MP0035). KPC-Arg2+/+ and KPC-Arg2−/− mouse PDA cell lines
were dissociated from corresponding mouse tumors39 in Hanks buffered saline
solution (HBSS, Invitrogen; calcium/magnesium free) containing 0.025%
trypsin–EDTA (Invitrogen) and 1 mgml−1 collagenase IV (Worthington
Biochemicals). Following a 2-h incubation with rotation at 37 °C, the samples were
triturated, pelleted, resuspended in HBSS, and ﬁltered through 40-μm cell strainers
(BD Falcon). All cells were maintained at 37 °C in a humidiﬁed incubator with
5% CO2 and were grown in RPMI-1640 (Sigma) supplemented with 10% fetal
bovine serum and penicillin-streptomycin (Gibco). For metabolic tracing studies
in vitro, the culture medium was optimized to exclude arginase activity in
10% serum, as detected by LC–MS. The cells were instead incubated in media
supplemented with 0.1% serum and 100 ng ml−1 IGF-1. Unless otherwise indicated,
all proliferation assays were also performed on cells cultured in 0.1% serum with
100 ng ml−1 IGF-1, using the proliferation kit II (XTT; Roche)32.
Expression plasmids. pBabe-neo-nlsCFP and pBabe-neo-ΔPH-myrAKT1
retroviral vectors were a gift from J. Albeck (UC Davis) who had generated them as
follows: For pBabe-neo-nlsCerulean, the sequence of Cerulean (a gift from David
Piston40) was subcloned into pBabe-neo with an SV40 nuclear localization
sequence at the 5′ terminus. For pBabe-neo-myr-AKT1(deltaPH)-HA, the
sequence for myr-AKT1(deltaPH)-HA was subcloned into pBabe-neo from
pWZLneo-myr-Akt(deltaPH)-ER, a gift from R. Roth41. pLJM15-neo-GFP was a
gift from D.M. Sabatini (Whitehead Institute). The short hairpin (sh)RNA-resistant
human ARG2 expression construct pLJM15-neo-hARG2-shA10R was generated
as follows: human ARG2 cDNA (Clone ID: 5179861) sequence from pCMV-
SPORT6-ARG2 (GE-Dharmacon MHS6278-202800846) was subcloned into
the lentiviral vector pLJM15-neo-polylinker (a gift from Dr. D.M. Sabatini)
using the AgeI/XbaI restriction sites. This construct was subsequently modiﬁed
by site-directed mutagenesis (QuikChange II Site-Directed Mutagenesis Kit,
Agilent 200521) using the following primers: shARG2-A10-resistant-F
(5′-ACACGTGCTTGATTTTCGGATTCGTCTGGGGAACTGGGAGTAG-
GAAG-3′) and shARG2-A10-resistant-R (5′-CTTCCTACTCCCAGTTCCCCA-
GACGAATCCGAAAATCAAGCACGTGT-3′). Retroviral and lentiviral
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00331-y ARTICLE
NATURE COMMUNICATIONS |8:  242 |DOI: 10.1038/s41467-017-00331-y |www.nature.com/naturecommunications 9
supernatants were generated by transfecting the above constructs into 293T cells
and used to infect AsPC-1 cells. The infected cells were selected for at least 7 days
1200 μg ml−1 G418 (Sigma-Aldrich, A1720).
Lentiviral-mediated shRNA targets. The RNAi consortium clone IDs for the
shRNAs used in this study are as follows: shARG2-A06 TRCN0000051018
(CGAACATTTGATCTGCTGATT); shARG2-A07 TRCN0000051019 (CCTATC-
GAGAAGGCATGTATA); shARG2-A10 TRCN0000051022 (GTTCACCA-
GATGAATCAGAAA); shARG2-B09 TRCN0000369866 (GAACTATGATA
TCCAGTATTT); shARG2-B10 TRCN0000333446 (CCCTTACCACTTCAT-
CAGGAA); shGFP TRCN0000072182 (TCTCGGCATGGACGAGCTGTA).
Scramble shRNA (CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGC-
GACTTAACCTTAGG) was from Addgene (Plasmid # 1864). For generation of
PDA cells with stable ARG2 or control (Scramble or GFP) knockdown, lentiviral
supernatants produced from pLKO plasmids encoding the corresponding hairpins
were used, and infected cells were selected for at least 7 days with 4 μg ml−1
puromycin (Sigma-Aldrich, P8833).
Animal work. All animal studies and procedures were approved by the Animal
Care and Use Committee at Boston Children’s Hospital. No statistical methods
were used to predetermine sample size. For orthotopic xenografts, 105 to 106 cells
suspended in 25 μl 33% Matrigel (BD Biosciences 356231) in HBSS were injected
into the pancreata of lean or obese male B6.129S7-Rag1tm1Mom/J mice termed
Rag1−/− mice (Jackson Laboratory #002216) at least 4 weeks after special diet
feeding. KPC-Arg2+/+ and KPC-Arg2−/− mice were generated by crossing KPC
mice or LSL-KrasG12D;p53ﬂ/ﬂ mice;pdx-1-Cre42, 43 (C57BL/6J-129 svJae) to
Arg2tm1Weo/J or Arg2−/− mice (C57BL/6J, Jackson Laboratory #020286). For
immune-proﬁcient orthotopic transplants models, 250,000–500,000 mouse PDA
cells derived from KPC tumors were orthotopically injected into littermates har-
boring wild-type Kras and Arg2 alleles. The experiments were not randomized. The
investigators were not blinded to allocation during experiments or outcome
assessment.
Diet feeding and plasma analysis. 4–12 week old mice were fed ad libitum either
a control chow diet (Harlan Teklad #7001, 3 Kcal g−1, 13% Kcal from fat) or a high
fat diet (D12492, Research Diets, 5.24 Kcal g−1, 60% Kcal from fat) and monitored
for several weeks. Body weight and food intake were measured and recorded
weekly. Glucose tolerance test after a 24-h fast was performed as previously
described44. Plasma glucose levels were measured using a glucose oxidase kit
(Thermo Fisher Scientiﬁc). Plasma insulin and IGF-I were assayed using kits from
CrystalChem and Diagnostic Systems Laboratories, respectively.
Necropsy. Mice were euthanized at the beginning of the light cycle after retro-
orbital blood withdrawal, and plasma was prepared as previously described44.
Tumors were collected, their dimensions (termed a, b and c) were measured
with a caliper and tumor volume was estimated according to the ellipsoid
formula45: 4/3 × π × (a/2 × b/2 × c/2). Tumors were then either immediately
frozen in liquid nitrogen, or ﬁxed in formalin for later processing.
Immunoblotting. Cells were rinsed once in ice-cold PBS and collected in lysis
buffer containing 50 mM HEPES, pH 7.4, 40 mM NaCl, 2 mM EDTA, 1.5 mM
orthovanadate, 50 mM NaF, 10 mM pyrophosphate, 10 mM glycerophosphate,
EDTA-free protease inhibitors (Roche) and 1% Triton X-100. Tumor tissues were
homogenized in lysis buffer supplemented with 1% deoxycholate and 0.1% SDS.
Proteins from total lysates were resolved by 8–12% SDS–PAGE, proteins were
transferred to polyvinylidene diﬂuoride and the blot was exposed to ﬁlm. In blots
assessing ARG1 and ARG2 levels, protein lysates from human hepatocellular
carcinoma HepG2 cells were used as a positive control. For all blots, glyceraldehyde
dehydrogenase (GAPDH) was used as a loading control. Protein band intensity was
quantiﬁed using Image J software (NIH). Scanned ﬁlms of uncropped blots are
shown in Supplementary Fig. 11.
Immunohistochemistry and analysis of human samples. Formalin-ﬁxed paraf-
ﬁn-embedded tumor samples were sectioned and immunostained according to the
manufacturers’ protocols. For human samples, a pathologist scored, in a blinded
fashion, the intensity of ARG2 and pS473-AKT staining in PDA cases on tissue
microarrays with 2–7 cores per case including non-neoplastic pancreatic tissue as
control. For ARG2 staining, the intensity was scored on a scale of 0–3 that
represented none (0), weak (1), moderate (2), and strong (3) based on the
staining seen in the majority of lesional cells. For pS473-AKT staining, scores
for each tumor core were estimated using the following formula: intensity score=
0 × (% area of tumor with no staining) + 1 × (% tumor area with moderate stain-
ing) + 2 × (% tumor area with strong staining), where 200 would be the highest
score. Analysis of human subjects included PDA tissue microarrays (TMAs) from
92 non-diabetic patients with surgically resected PDA (58 from Massachusetts
General Hospital or MGH and 34 from Dana-Farber/Brigham and Women’s
Cancer Center or DF/BWCC). For MGH patients, informed consent was waived
by the Institutional Review Board or IRB (Protocol Number 2009P001838), as
the TMAs were generated from discarded material following clinical diagnosis.
For DF/BWCC patients, informed consent for use of clinical data and tissue
specimens was obtained with approval by the Dana-Farber/Harvard Cancer Center
or DF/HCC IRB (Protocol Numbers 03-189 and 02-023). Patient height and weight
were obtained from preoperative evaluation within 2 weeks before surgery and
used to calculate BMI, which was modeled as a continuous variable. pAKT and
ARG2 were evaluated as dichotomous categorical variables. Levels of each protein
were classiﬁed as “high” if≥ 25th percentile stain score among the 92 samples.
Analyses of the associations between BMI, pAKT, and ARG2 levels were conducted
using binomial logistic regression, obtaining odds ratios (ORs) and 95% conﬁdence
intervals (95% CI). The ORs reﬂect the odds per unit increase in BMI (kg m−2) for
a high ARG2 expressing tumor, or the odds of high versus low-pAKT levels for a
high-ARG2 expressing tumor. Regression models were adjusted for age at surgery,
sex, and American Joint Committee on Cancer (AJCC) 7th edition pathological
stage (IA-IIA, IIB-III). All hypothesis tests were two-sided. Statistical signiﬁcance
was set at α= 0.05. Analyses were performed using SAS software (version 9.4, SAS
Institute, Cary, NC).
Gene expression proﬁling and GSEA. Tumor tissues were homogenized and
control AsPC1-CFP cultured cells were lysed in QIAzol lysis reagent and total RNA
was extracted using the RNeasy Microarray Tissue Mini Kit (Qiagen). RNA
quality was checked using the Bioanalyzer RNA Nano kit, and 325 ng were used
for microarray labeling with the Agilent LowInput QuickAmp Labeling Kit
Two-Color. Dye incorporation and yield were measured with a Nanodrop
spectrophotometer. Equal amounts of differentially labeled control AsPC1-CFP
cells propagated in culture and sample cRNA were combined such that each
sample contained at least 2.5 pmol dye. Samples were mixed with control targets,
fragmented, combined with hybridization buffer, and hybridized to the SurePrint
G3 Human Gene Expression 8 × 60 K v2 Microarray consisting of 60mer probes for
each human open reading frame (Agilent). Microarrays were rotated at 60 °C for
17 h in a hybridization oven (Agilent). Arrays were then washed according to the
Agilent SSPE wash protocol, and scanned on an Agilent scanner. The image was
processed using the default settings with Agilent Feature Extraction software. All
data analysis was performed using the resulting log(2) ratio data of tumor
samples over AsPC1-CFP cell line control samples, and ﬁltered for spots called as
signiﬁcantly over background in at least one channel. For GSEA22, 46, gene sets
collection from Kyoto Encyclopedia of Genes and Genomes (KEGG) were included
in the analysis to assess the enrichment of the obese and AKT gene signatures.
A pairwise GSEA was performed by creating ranked lists of genes using the
difference of class means to calculate fold change for log scale data between the
Lean-CFP and Obese-CFP (Fig. 1d) or between Lean-CFP and the rest of the
tumors grouped together (Obese-CFP, Lean-AKT and Obese-AKT, Fig. 4f) and
P values were obtained from permuting the gene set (1000 permutations).
Metabolite extraction and quantiﬁcation. Tissues (10–30 mg) were homogenized
using a Qiagen TissueLyzer II in 1:4 (w:v) water. 10 µl of each tissue homogenate
was combined with 90 µl of extraction solution (acetonitrile:methanol:formic acid
(75:25,0.2v:v:v), 0.2 ng µl−1 d8-phenylalanine and d8-valine), vortexed, centrifuged
(10 min, 10,000 × g, 4 °C) and the supernatants collected and stored (−80 °C) for
metabolite proﬁling. Data were acquired using a hydrophilic interaction liquid
chromatography method (HILIC) with positive ion mode Mass Spectrometry (MS)
operated on Nexera X2 UHPLC (Shimadzu Scientiﬁc Instruments, Marlborough,
MA) coupled to a Q Exactive orbitrap mass spectrometer (Thermo Fisher
Scientiﬁc, Waltham, MA) as described previously47, with data collected in the
70–800m/z range. For experiments measuring urea, data were collected in
the 55–750m/z range. The supernatants (10 µl) were injected directly onto a
150 × 2mm Atlantis HILIC column (Waters; Milford, MA). The column
was eluted isocratically at a ﬂow rate of 250 μl min−1 with 5% mobile phase A
(10 mM ammonium formate and 0.1% formic acid in water) for 1 min followed by
a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid)
over 10 min. The electrospray ionization voltage was 3.5 kV. LC–MS data were
processed and visually inspected using TraceFinder 3.3 software. For global steady-
state metabolite proﬁling, data were generated by Metaboanalyst 3.048, median-
normalized, log-transformed, mean-centered and divided by the s.d. of each
variable. In addition to LC–MS, urea levels were quantiﬁed using a urea assay kit
(Sigma #MAK006). For metabolic tracing in cultured cells, dried extracts were
suspended in 100 µl water. After centrifugation at top speed for 10 min, 2 µl of
supernatant was injected for LC/MS analysis as described in ref. 49.
Ammonia derivatization. In total 10 μl of 1 mM ethylamine internal standard
(in water) was directly added to tissue chunks, followed by addition of 250 μl of
0.5 mg ml−1 dansyl chloride (in acetonitrile) and homogenization on ice. The
homogenates were centrifuged at top speed at 4 °C for 5 min, the supernatants
collected and incubated at 70 °C for 5 h, followed by centrifugation at top speed at
4 °C for 5 min. The supernatants were then stored at −80 °C. In total 1 μl of
supernatant was injected for LC–MS analysis. Chromatographic separation was
performed on a Dionex Ultimate 3000 UPLC system using a Kinetex 50 × 2.1 mm
C18 (100 Å, 2.6 μm particle size) column (Phenomenex). The mobile phases were
0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile
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(mobile phase B). The ﬂow rate was held at 0.4 ml min−1 and the column com-
partment was held at 35 °C. The chromatographic gradient was as follows: 0–3.5
min.: linear increase from 5% B to 80% B; 3.5–3.6 min: linear increase from 80% B
to 98% B; 3.6–4.5 min.: hold at 98% B; 4.5–4.6 min.: linear decrease from 98% B to
5% B; 4.6–6.0 min.: hold at 5% B. The column eluate was introduced directly into
the ionization source of a QExactive benchtop orbitrap mass
spectrometer (Thermo Fisher Scientiﬁc) equipped with a HESI probe. The
mass spectrometer was operated in positive ionization mode, using targeted
selected ion monitoring (tSIM) scans with target windows of width 2.0m/z
centered at m/z= 251.5834 (to include dansylated ammonia and 15N-ammonia)
and m/z= 279.1162 (to include dansylated ethylamine). The resolution was set to
140,000, the AGC target was set to 1e5, and the maximum integration time was set
to 250 ms. The spray voltage was set to 3.0 kV, the capillary temperature was set to
275 °C, the sheath gas was set to 40 units, the auxiliary gas was set to 15 units, and
the spare gas was set to 1 unit. The probe heater temperature was set to 350 °C and
the S-lens RF level set to 40 units. External mass calibration was performed using
the standard calibration mixture every 7 days. Data were analyzed using XCalibur
QuanBrowser v2.2 (Thermo Fisher Scientiﬁc). The chromatographic retention
times of the derivatization products were conﬁrmed by analyzing a derivatization
reaction containing pure ammonia and ethylamine. The relative abundance of
15N-ammonia (Fig. 3h) is reported as the raw peak area of dansylated
15N-ammonia divided by the raw peak area of dansylated ethylamine, whereas the
fraction labeled is reported as the raw peak area of dansylated 15N-ammonia
divided by the summed raw peak areas of dansylated 15N- and unlabeled ammonia.
Infusion of labeled nutrients. Infusions were performed as previously described
in ref. 38. Speciﬁcally, lean or obese immunodeﬁcient mice bearing human
orthotopic pancreatic xenografts were infused 3 weeks after the injection of
tumor cells, with 15N(amine)-glutamine (99% enrichment; Cambridge Isotope
Laboratories, Andover, MA) as a bolus of 0.28 mg g−1 body weight (0.3 ml)
administered over 1 min, followed by a continuous infusion of 0.005 mg g−1 min−1
for 180 min. Alternatively, immune-proﬁcient lean or obese mice bearing mouse
orthotopic transplant tumors were infused 2 weeks after the injection of tumor
cells, with 13C6,15N4-arginine.HCl (13C6, 99%; 15N4, 99% enrichment, Cambridge
Isotope Laboratories, Andover, MA) as a bolus of 0.084 mg g−1 body weight
(0.3 ml) over 1 min, followed by a continuous infusion of 0.0015 mg g−1 min−1 for
180 min. In total 25 μl of tail blood was collected at 30 min intervals and used to
quantify plasma enrichment of labeled nutrients by LC–MS. At the end of the
infusions, mice were euthanized and the tumors rapidly harvested, weighed and
snap-frozen in liquid nitrogen for LC–MS analysis.
Statistics. Statistical analyses are expressed as mean ± s.d., or s.e.m., unless
otherwise indicated. No statistical methods were used to predetermine sample size.
In comparing two groups, a two-tailed non-paired Student t-test was conducted.
For three or more groups, one-way ANOVA was conducted, except for growth
curves (two-way ANOVA), followed by a post hoc Tukey test. P≤ 0.05 was
considered statistically signiﬁcant. For GSEA and metabolic pathway analysis, a
FDR q-value ≤ 0.25 was considered signiﬁcant.
Data availability. The microarray data have been deposited in NCBI’s Gene
Expression Omnibus50 and are accessible through GEO Series accession number
GSE99289. The authors declare that all the other data supporting the ﬁndings of
this study are available within the article, its Supplementary Information and from
the corresponding author upon reasonable request.
Received: 26 April 2017 Accepted: 21 June 2017
References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. Cancer. J. Clin. 66,
7–30 (2016).
2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected
burden of thyroid, liver, and pancreas cancers in the United States. Cancer. Res.
74, 2913–2921 (2014).
3. Bracci, P. M. Obesity and pancreatic cancer: overview of epidemiologic
evidence and biologic mechanisms. Mol. Carcinog. 51, 53–63 (2012).
4. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight,
obesity, and mortality from cancer in a prospectively studied cohort of U.S.
adults. N. Engl. J. Med. 348, 1625–1638 (2003).
5. Li, D. et al. Body mass index and risk, age of onset, and survival in patients with
pancreatic cancer. JAMA 301, 2553–2562 (2009).
6. Rebours, V. et al. Obesity and fatty pancreatic inﬁltration are risk factors for
pancreatic precancerous lesions (PanIN). Clin. Cancer. Res. 21, 3522–3528
(2015).
7. Yuan, C. et al. Prediagnostic body mass index and pancreatic cancer survival.
J. Clin. Oncol. 31, 4229–4234 (2013).
8. Perera, R. M. & Bardeesy, N. Pancreatic cancer metabolism: breaking it down to
build it back up. Cancer Discov. 5, 1247–1261 (2015).
9. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-
regulated metabolic pathway. Nature 496, 101–105 (2013).
10. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation
of anabolic glucose metabolism. Cell 149, 656–670 (2012).
11. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route
in Ras-transformed cells. Nature 497, 633–637 (2013).
12. Guo, J. Y. et al. Activated Ras requires autophagy to maintain oxidative
metabolism and tumorigenesis. Genes Dev. 25, 460–470 (2011).
13. Kamphorst, J. J. et al. Human pancreatic cancer tumors are nutrient poor and
tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544–553
(2015).
14. Perera, R. M. et al. Transcriptional control of autophagy-lysosome function
drives pancreatic cancer metabolism. Nature. 524, 361–365 (2015).
15. Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes
Dev. 25, 717–729 (2011).
16. Davidson, S. M. et al. Direct evidence for cancer-cell-autonomous extracellular
protein catabolism in pancreatic tumors. Nat. Med. 23, 235–241 (2016).
17. Deignan, J. L., Cederbaum, S. D. & Grody, W. W. Contrasting features of urea
cycle disorders in human patients and knockout mouse models. Mol. Genet.
Metab. 93, 7–14 (2008).
18. Iyer, R. K. et al. Mouse model for human arginase deﬁciency. Mol. Cell Biol. 22,
4491–4498 (2002).
19. Kasten, J. et al. Lethal phenotype in conditional late-onset arginase 1 deﬁciency
in the mouse. Mol. Genet. Metab. 110, 222–230 (2013).
20. Sin, Y. Y. et al. Inducible arginase 1 deﬁciency in mice leads to
hyperargininemia and altered amino acid metabolism. PLoS ONE 8, e80001
(2013).
21. Shi, O., Morris, S. M. Jr, Zoghbi, H., Porter, C. W. & O’Brien, W. E. Generation
of a mouse model for arginase II deﬁciency by targeted disruption of the
arginase II gene. Mol. Cell Biol. 21, 811–813 (2001).
22. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression proﬁles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
23. Mottier, N. & Jeanneret, F. Evaluation of two derivatization reagents for the
determination by LC-MS/MS of ammonia in cigarette mainstream smoke.
J. Agric. Food Chem. 59, 92–97 (2011).
24. Renehan, A. G., Zwahlen, M. & Egger, M. Adiposity and cancer risk:
new mechanistic insights from epidemiology. Nat. Rev. Cancer 15, 484–498
(2015).
25. Davidson, S. M. et al. Environment impacts the metabolic dependencies of
ras-driven non-small cell lung cancer. Cell Metab. 23, 517–528 (2016).
26. Albury, T. M. et al. Constitutively active Akt1 cooperates with KRas(G12D) to
accelerate in vivo pancreatic tumor onset and progression. Neoplasia 17,
175–182 (2015).
27. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human
cancer cells. Cancer Cell. 7, 561–573 (2005).
28. Wolpin, B. M. et al. Hyperglycemia, insulin resistance, impaired pancreatic
beta-cell function, and risk of pancreatic cancer. J. Natl. Cancer. Inst. 105,
1027–1035 (2013).
29. Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M. & Abbruzzese, J. L.
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 137,
482–488, doi:10.1053/j.gastro.2009.04.013 (2009).
30. Lashinger, L. M. et al. Dietary energy balance modulation of Kras- and Ink4a/
Arf+/−-driven pancreatic cancer: the role of insulin-like growth factor-1.
Cancer Prev. Res. 6, 1046–1055 (2013).
31. Roberts, D. L., Dive, C. & Renehan, A. G. Biological mechanisms linking
obesity and cancer risk: new perspectives. Annu. Rev. Med. 61, 301–316 (2010).
32. Kalaany, N. Y. & Sabatini, D. M. Tumours with PI3K activation are resistant to
dietary restriction. Nature. 458, 725–731 (2009).
33. Kashyap, S. R., Lara, A., Zhang, R., Park, Y. M. & DeFronzo, R. A. Insulin
reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 31,
134–139 (2008).
34. Morris, S. M. Jr, Gao, T., Cooper, T. K., Kepka-Lenhart, D. & Awad, A. S.
Arginase-2 mediates diabetic renal injury. Diabetes 60, 3015–3022 (2011).
35. Pernow, J., Kiss, A., Tratsiakovich, Y. & Climent, B. Tissue-speciﬁc up-
regulation of arginase I and II induced by p38 MAPK mediates endothelial
dysfunction in type 1 diabetes mellitus. Br. J. Pharmacol. 172, 4684–4698
(2015).
36. Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164,
681–694, doi:10.1016/j.cell.2015.12.034 (2016).
37. Maher, E. A. et al. Metabolism of [U-13 C]glucose in human brain tumors
in vivo. NMR Biomed. 25, 1234–1244 (2012).
38. Marin-Valencia, I. et al. Analysis of tumor metabolism reveals mitochondrial
glucose oxidation in genetically diverse human glioblastomas in the mouse
brain in vivo. Cell. Metab. 15, 827–837 (2012).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00331-y ARTICLE
NATURE COMMUNICATIONS |8:  242 |DOI: 10.1038/s41467-017-00331-y |www.nature.com/naturecommunications 11
39. Curry, N. L. et al. Pten-null tumors cohabiting the same lung display
differential AKT activation and sensitivity to dietary restriction. Cancer Discov.
3, 908–921 (2013).
40. Rizzo, M. A., Springer, G. H., Granada, B. & Piston, D. W. An improved cyan
ﬂuorescent protein variant useful for FRET. Nat. Biotechnol. 22, 445–449 (2004).
41. Kohn, A. D. et al. Construction and characterization of a conditionally active
version of the serine/threonine kinase Akt. J. Biol. Chem. 273, 11937–11943
(1998).
42. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its
early detection in the mouse. Cancer Cell 4, 437–450 (2003).
43. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a
conditional mouse model for breast cancer. Nat. Genet. 29, 418–425 (2001).
44. Kalaany, N. Y. et al. LXRs regulate the balance between fat storage and
oxidation. Cell Metab. 1, 231–244 (2005).
45. Wapnir, I. L., Wartenberg, D. E. & Greco, R. S. Three dimensional staging of
breast cancer. Breast Cancer Res. Treat. 41, 15–19 (1996).
46. Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative
phosphorylation are coordinately downregulated in human diabetes.
Nat. Genet. 34, 267–273, doi:10.1038/ng1180 (2003).
47. Mascanfroni, I. D. et al. Metabolic control of type 1 regulatory T cell
differentiation by AHR and HIF1-alpha. Nat. Med. 21, 638–646 (2015).
48. Xia, J. & Wishart, D. S. Using MetaboAnalyst 3.0 for comprehensive
metabolomics data analysis. Curr. Protoc. Bioinf. 55, 14 10 11–14 10 91 (2016).
49. Birsoy, K. et al. An essential role of the mitochondrial electron transport chain
in cell proliferation is to enable aspartate synthesis. Cell 162, 540–551 (2015).
50. Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Res. 30,
207–210 (2002).
Acknowledgements
We thank J. Albeck for the pBabe-neo-nlsCFP and pBabe-neo-ΔPH-myrAKT1 plasmids,
D.M. Sabatini for the PLJM15-neo plasmids, Z.R. Qian for help with tumor samples and
K. Honselmann for help with patient records, I. Ben-Sahra, R.A. Weinberg and R. Fine
for helpful comments and discussions. This work was supported by funds from Boston
Children’s Hospital (T.Z., P.-Y.T., C.D.D., and N.Y.K.), the V Foundation for Cancer
Research V Scholar Award (N.Y.K.), the American Diabetes Association Junior Faculty
Award (N.Y.K.), the Children’s Hospital-Broad Institute Collaboration Grant (N.Y.K.)
and Pancreatic Cancer Action Network-AACR Career Development Award (N.Y.K.).
N.Y.K. also holds a DFHCC SPORE in Gastrointestinal Cancer Developmental Project
Award (P50CA127003), a Hirshberg Foundation for Pancreatic Cancer Research Seed
Grant and a American Cancer Society Research Scholar Grant. P.J.L. was funded by
award T32GM007753 from the National Institute of General Medical Sciences (NIGMS).
The content is solely the responsibility of the authors and does not necessarily represent
the ofﬁcial views of the NIGMS or National Institutes of Health.
Author contributions
N.Y.K. conceived and designed the study. T.Z. performed all experiments. P.-Y.T. and
C.D.D. assisted T.Z. in cell culture, proliferation assays, and western blots. D.S.H.
performed and T.Z. and D.S.H. analyzed metabolite measurements. C.B.C. supervised the
metabolite quantiﬁcation and analyses. E.F. performed ammonia derivatization and
quantiﬁcation of urea and ammonia by mass spectrometry. P.J.L. performed the
immunochemistry on tissue sections. M.M.-K. and B.M.W. provided tissue microarrays.
M.M.-K. provided pathological assessment and scoring for immunostained human
pancreatic tissue. V.M.-O. performed the statistical analysis on the human data. B.M.W.
supervised the human analysis and along with V.M.-O., contributed to the discussion of
the results. E.M.T. performed and analyzed the expression microarrays and was helped
by T.Z. N.S. optimized and performed with the help of T.Z., the orthotopic PDA tumor
cell injections. L.L. performed the in vivo infusions and was assisted by T.Z. N.Y.K.
supervised all experimental analyses. N.Y.K. and T.Z. wrote the manuscript with
feedback from all authors.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00331-y.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00331-y
12 NATURE COMMUNICATIONS | 8:  242 |DOI: 10.1038/s41467-017-00331-y |www.nature.com/naturecommunications
